ZA984268B - Method and composition for administering taxanes orally to human patients - Google Patents

Method and composition for administering taxanes orally to human patients

Info

Publication number
ZA984268B
ZA984268B ZA984268A ZA984268A ZA984268B ZA 984268 B ZA984268 B ZA 984268B ZA 984268 A ZA984268 A ZA 984268A ZA 984268 A ZA984268 A ZA 984268A ZA 984268 B ZA984268 B ZA 984268B
Authority
ZA
South Africa
Prior art keywords
composition
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
ZA984268A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of ZA984268B publication Critical patent/ZA984268B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA984268A 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients ZA984268B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27

Publications (1)

Publication Number Publication Date
ZA984268B true ZA984268B (en) 1999-06-23

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984268A ZA984268B (en) 1997-05-27 1998-05-20 Method and composition for administering taxanes orally to human patients

Country Status (23)

Country Link
EP (1) EP0994706B1 (fr)
JP (1) JP2002500667A (fr)
KR (1) KR100615783B1 (fr)
CN (2) CN1261275A (fr)
AR (1) AR012731A1 (fr)
AT (1) ATE308365T1 (fr)
AU (1) AU7130098A (fr)
BR (1) BR9809694A (fr)
CA (1) CA2290446C (fr)
CZ (1) CZ9904244A3 (fr)
DE (1) DE69832173T2 (fr)
DK (1) DK0994706T3 (fr)
ES (1) ES2247690T3 (fr)
HK (1) HK1026637A1 (fr)
HU (1) HUP0003546A3 (fr)
IL (2) IL132992A0 (fr)
NO (1) NO995812L (fr)
PL (1) PL337064A1 (fr)
RU (1) RU2205005C2 (fr)
SK (1) SK157599A3 (fr)
UA (1) UA74767C2 (fr)
WO (1) WO1998053811A1 (fr)
ZA (1) ZA984268B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
DE69713526D1 (de) * 1997-06-20 2002-07-25 Baker Norton Pharma Lösliche prodrugs von paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1749540B1 (fr) 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions pour ameliorer la biodisponibilite des medicaments administres par voie orale
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
EP1365759A2 (fr) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Preparations de microemulsion chimiotherapeutique de paclitaxel presentant une meilleure biodisponibilite orale
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1623706A3 (fr) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Dosage métronomique de taxanes pour l'inhibition de la croissance tumorale
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2010141584A2 (fr) * 2009-06-02 2010-12-09 Nikan Pharmaceuticals, Llc Antagonisme du récepteur du peptide formyl humain dans le traitement de maladies
CA3212816A1 (fr) * 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa Inhibiteurs de c5ar1 pour le traitement de reactions d'hypersensibilite a des taxanes
EP4059497A1 (fr) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibiteurs pour le traitement des réactions d'hypersensibilité aux taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
AU652996B2 (en) * 1991-01-11 1994-09-15 Laboratoires Glaxo S.A. Acridine derivatives
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
DE69507702T2 (de) * 1994-07-26 1999-08-26 Indena Spa Semisynthetisch taxal derivate mit antitumor wirkung
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (fr) * 1996-01-31 1997-08-07 Steven B. Hansel Procede permettant de rendre actifs du point de vue pharmaceutique des taxanes assimilables par voie orale
EP0814081A1 (fr) * 1996-06-17 1997-12-29 Eli Lilly And Company Modulateurs résistants aux médicaments multiples
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1999049848A1 (fr) * 1998-04-01 1999-10-07 Rtp Pharma Inc. Compositions anticancereuses

Also Published As

Publication number Publication date
KR20010013025A (ko) 2001-02-26
ATE308365T1 (de) 2005-11-15
JP2002500667A (ja) 2002-01-08
EP0994706B1 (fr) 2005-11-02
NO995812D0 (no) 1999-11-26
CA2290446C (fr) 2008-01-29
HUP0003546A2 (hu) 2002-11-28
WO1998053811A1 (fr) 1998-12-03
BR9809694A (pt) 2000-10-03
ES2247690T3 (es) 2006-03-01
CZ9904244A3 (cs) 2001-10-17
PL337064A1 (en) 2000-07-31
CN1550231A (zh) 2004-12-01
KR100615783B1 (ko) 2006-08-25
HK1026637A1 (en) 2000-12-22
DE69832173T2 (de) 2006-08-03
DK0994706T3 (da) 2006-03-06
UA74767C2 (en) 2006-02-15
HUP0003546A3 (en) 2002-12-28
RU2205005C2 (ru) 2003-05-27
CA2290446A1 (fr) 1998-12-03
AR012731A1 (es) 2000-11-08
IL132992A0 (en) 2001-03-19
SK157599A3 (en) 2002-10-08
DE69832173D1 (de) 2005-12-08
CN1261275A (zh) 2000-07-26
IL132992A (en) 2006-08-20
AU7130098A (en) 1998-12-30
NO995812L (no) 2000-01-25
EP0994706A4 (fr) 2001-05-16
EP0994706A1 (fr) 2000-04-26

Similar Documents

Publication Publication Date Title
PL341592A1 (en) Method of administering human aspb28 insulin
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
AU1805499A (en) Method and apparatus for delivery of therapeutic agents to the heart
HK1151462A1 (zh) 用於將物質給藥的植入物以及製備植入物的方法
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
PL344246A1 (en) Novel pharmaceutical composition for use in emergency treatment and preparation method thereof
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
ZA984268B (en) Method and composition for administering taxanes orally to human patients
EP1129217A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter des maladies
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
PL341230A1 (en) Solid dosage forms of ribavirin for oral administration and method of obtaining them
IL122405A (en) Methods for preparation of pharmaceutical composition for treatment of specific diseases using oils enriched in dha
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
EP1181022A4 (fr) Compositions medicinales et leur procede de preparation
EP1210075A4 (fr) Compositions et methodes pour modifier le taux de lipides cutanes
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0001526A3 (en) Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
ZA964517B (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
EP1009433A4 (fr) Composition therapeutique et procede de traitement
AU784159C (en) Method and compositions for administering taxanes orally to human patients
HUP0203676A3 (en) Pharmaceutical composition and method for treatment of diabetes
HUP9801869A3 (en) Pharmaceutical composition for enhancing level of l-carnitin in human patients
GB9608927D0 (en) Method of treatment and pharmaceutical composition